Company Performance Metrics
Katherine S. Bowdish: President & CEOPast Role: Sanofi, Vice President Global R&D and Head of Sunrise
Richard Peters: Founding Investor and DirectorPast Role: X4 Pharmaceuticals, Co-Founder, Investor, and Director
PIC Therapeutics is a biotechnology company focused on transforming the treatment of cancer through the selective modulation of oncogene translation. The company is modulating oncogene translation to dramatically improve cancer patient outcomes. Their precision-based therapeutics target the “master switch” of cancer signaling pathways, selectively
blocking oncogene protein production by modulating the Pre-Initiation Complex (PIC) that drives their mRNA translation. Its selective approach has the potential to simultaneously modulate multiple oncogenic drivers leading to a powerful new generation of cancer-treating therapeutics.
PIC Therapeutics was founded in 2016 and is headquartered in Natick, Massachusetts, United States.